{"id":"W4396586818","doi":"10.1158/1538-7445.sabcs23-ps17-07","title":"Abstract PS17-07: Interim analysis of giredestrant + inavolisib in MORPHEUS Breast Cancer: a Phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Breast cancer; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Cancer; Estrogen receptor; Interim analysis; HER2 negative; Interim; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002432119,0.001915086,0.003418728,0.0006549494,0.0004921913,0.001388326,0.0009939764,0.001197531,0.007774679],"category_scores_gemma":[0.001371681,0.0006504534,0.002787058,0.000544842,0.001017099,0.001079726,0.000481456,0.004240131,0.001848934],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000996761,"about_ca_system_score_gemma":0.001911693,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009791781,"about_ca_topic_score_gemma":0.002040442,"domain_scores_codex":[0.9993191,0.000302593,0.00003467487,0.00009109356,0.00006592043,0.000186653],"domain_scores_gemma":[0.9989473,0.0001514698,0.000185308,0.0001259675,0.00008216143,0.0005078174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9193702,0.02457713,0.003077807,0.0004362083,0.001599333,0.0001263229,0.00008801366,0.002334092,0.01341559,0.0002169422,0.003474294,0.031284],"study_design_scores_gemma":[0.426511,0.5515053,0.01028122,0.00004876657,0.001444242,0.0002138251,0.00008632091,0.001388125,0.003541667,0.0004880796,0.004441166,0.00005037479],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796956,0.002447071,0.001097496,0.0006663479,0.0003684466,0.005198346,0.00650525,0.0002400626,0.003781432],"genre_scores_gemma":[0.9664075,0.002086875,0.003016462,0.001323678,0.0002725161,0.008389525,0.01021652,0.0001048386,0.008182203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007774679,"threshold_uncertainty_score":0.0260089,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09188087022298844,"score_gpt":0.4811329786448584,"score_spread":0.38925210842187,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}